International – Nations raise concerns about access to remdesivir

Earlier this week (June 29), the US Department of Health and Human Services (HHS) announced a purchase agreement with Gilead for remdesivir. HHS said they have staked claim to 100 percent of Gilead’s projected production for July (94,200 treatment courses), 90 percent of production in August (174,900 treatment courses), and 90 percent of production in September (232,800 treatment courses), in addition to an allocation for clinical trials. (When asked today, Gilead said 90% of the drug is committed to the US for this period).

HHS Secretary Alex Azar commented that “President Trump has struck an amazing deal to ensure Americans have access to the first authorized therapeutic for COVID-19.”…